乙型肝炎病毒基因型与抗病毒药物疗效关系的研究进展

邓乐; 温志立

乙型肝炎病毒基因型与抗病毒药物疗效关系的研究进展

邓乐,
温志立

1. 南昌大学研究生院医学部
2. 南昌大学第三附属医院感染性疾病科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 3122
- HTML全文浏览量: 27
- PDF下载量: 649
- 被引次数: 0
出版历程
- 出版日期: 2012-06-20

Review of recent research progress in correlating HBV genotypes with efficacy of antiviral treatments

Deng Le,
Wen ZhiLi

摘要

摘要: 乙型肝炎在全球发病率高,严重危害人类健康。随着HBV基因型研究的深入,大量研究显示HBV基因型与临床疾病谱密切相关。目前抗病毒治疗是慢性乙型肝炎治疗的最主要措施,越来越多的学者对HBV基因型与抗病毒药物疗效的关系进行了研究,本文就目前国内外关于HBV基因型与抗病毒疗效关系的研究进展作一综述。
- 肝炎,乙型 /
- 肝炎病毒,乙型 /
- 抗病毒药 /
- 基因型
Abstract: Hepatitis B is one of the most prevalent infectious diseases worldwide.Moreover, chronic hepatitis B virus (HBV) infection is strongly associated with subsequent development of life-threatening hepatic diseases, such as heptocellular carcinoma, decompensated cirrhosis, and advanced fibrosis.Extensive studies of the various HBV genotypes have uncovered a close correlated with clinical factors, which may help to design and implement effective therapeutic strategies for treating infections with the different genotypes.Since antivirus therapy remains the main treatment for hepatitis B, research studies have focused on determining the relations between the various HBV genotypes and efficacy of the currently available antiviral drugs.In this review, we systematically discuss the recent findings from the literature on HBV genotype correlations with efficacy of antivirus treatment.
- hepatitis B /
- hepatitis B virus /
- antiviral agents /
- genotype

HTML全文

参考文献(50)

[1]Norder H, Courouce AM, Magnius LO.Complete genomes, phylo-genetic relatedness, and structural proteins of six strains of the hepa-titis B virus, four of which represent two new genotypes[J].Virolo-gy, 1994, 198 (2) :489-503.

[2]Okamoto H, Tsuda F, Sakugawa H, et al.Typing hepatitis B virusby homologv in nucleotide sequence:comparison of surface antigensubtypes[J].J Gen Virol, 1988, 69 (10) :2575-2583.

[3]Stuyver L, De Gendt S, Van Geyt C, et al.A new genotype of hep-atitis B virus:complete genome and phylogenetic relatedness[J].JGen Virol, 2000, 81 (1) :67-74.

[4]Arankalle VA, Gandhe SS, Borkakoty BJ, et al.A novel HBV re-combinant (genotype I) similar to Vietnam/Laos in a primitive tribein eastern India[J].J Viral Hepatol, 2010, 17 (7) :501-510.

[5]Fuminaka S, Anuchit C, Etsuro O, et al.Hepatitis B virus geno-types and clinical manifestation among hepatitis B carriers in Thai-land[J].J Gastroenterol Hepatol, 2002, 17 (6) :671-676.

[6]Mota A, Guedes F, Areias J, et al.Epidemiological study of geno-types of hepatitis B virus in northern Portugal[J].J Med Virol, 2009, 81 (7) :1170-1176.

[7]Baig S, Siddiqui AA, Ahmed W, et al.The association of complexliver disorders with HBV genotypes prevalent in Pakistan[J].VirolJ, 2007, 27 (4) :128.

[8]Tonetto PA, Goncales NS, Fais VC, et al.Hepatitis B virus:mo-lecular genotypes and HBeAg serological status among HBV-infec-ted patients in the southeast of Brazil[J].BMC Infect Dis, 2009, 8 (9) :149.

[9]Madan K, Batra Y, Sreenivas V, et al.HBV genotypes in India:do they influence disease severity?[J].Hepatol Res, 2009, 39 (2) :157-163.

[10] 温志立, 邓青, 张华, 等.采用多对型特异性引物巢式PCR法研究江西省HBV基因型分布及其临床相关性[J].中华微生物学和免疫学杂志, 2009, 29 (2) :175-176.

[11]Niu J, He S, Su C, et al.Variability of the S gene of hepatitis B vi-rus in southeastern China[J].Arch Virol, 2010, 155 (12) :1951-1957.

[12]Sherman M.Risk of hepatocellular carcinoma in hepatitis B andprevention through treatment[J].Cleve Clin J Med, 2009, 76 (Suppl 3) :6-9.

[13]Pujol FH, Navas MC, Hainaut P, et al.Worldwide genetic diversi-ty of HBV genotypes and risk of hepatocellular carcinoma[J].Cancer Lett, 2009, 286 (1) :80-88.

[14]Liang TJ, Mok KT, Liu SI, et al.Hepatitis B genotype C correlatedwith poor Surgical outcomes for hepatocellular carcinoma[J].J AmColl Surg, 2010, 211 (5) :580-586.

[15]Hassan ZK, Hafez MM, Mansor TM, et al.Occult HBV infectionamong Egyptian hepatocellular carcinoma patients[J].Virol J, 2011, 8 (1) :90.

[16]Lin CL, Kao JH.The clinical implications of hepatitis B virus geno-type:Recent advances[J].J Gastroenterol Hepatol, 2011, 26 (Suppl 1) :123-130.

[17]Ali L, Idrees M, Ali M, et al.An overview of treatment responserates to various anti-viral drugs in Pakistani hepatitis B virus infec-ted patients[J].Virol J, 2011, 15 (8) :20.

[18]Raimondi, Sara M, Patrick B, et al.Is response to antiviral treat-ment influenced by hepatitis B virus genotype?[J].J Hepatol, 2010, 52 (3) :441-449.

[19]Zhu CT, Dong CL.Characteristics of general distribution of hepati-tis B virus genotypes in China[J].Hepatobiliary Pancreat Dis Int, 2009, 8 (4) :397-401.

[20]于秀艳, 汪杰, 刘鹏, 等.乙型肝炎病毒基因型与干扰素抗病毒治疗相关性的探讨[J].中国实验诊断学, 2009, 13 (1) :115-116.

[21]蔡艳萍, 黄元成, 张美珍, 等.乙肝病毒基因型对武汉地区慢性乙型肝炎患者干扰素α-2b疗效的影响[J].中西医结合肝病杂志, 2010, 20 (2) :83-85.

[22]肖扬, 周岳进, 郑金莉, 等.乙型肝炎病毒基因型和早期病毒学应答对干扰素α-2b治疗慢性乙型肝炎疗效的预测价值[J].实用肝脏病杂志, 2009, 12 (1) :23-24, 80.

[23]Zhao H, Kurbanov F, Wan MB, et al.Genotype B and younger pa-tient age associated with better response to low-dose therapy:a tri-al with pegylated/nonpegylated interferon-alpha-2b for hepatitisB e antigen-positive patients with chronic hepatitis B in China[J].Clin Infect Dis, 2007, 44 (4) :541-548.

[24]Alfaresi M, Elkoush A, Alshehhi A, et al.Hepatitis B virus geno-types and precore and core mutants in UAE patients[J].Virol J, 2010, 15 (7) :160.

[25]Antaki N, Haffar S, Ali Deeb S, et al.High prevalence of HBVgenotype D in Syria and the clinical characteristics of hepatitis B eantigen-negative chronic hepatitis B[J].Epidemiol Infect, 2010, 138 (1) :40-44.

[26]Sharma S, Sharma B, Singla B, et al.Clinical significance of geno-types and precore/basal core promoter mutations in HBV relatedchronic liver disease patients in North India[J].Dig Dis Sci, 2010, 55 (3) :794-802.

[27]Hou J, Schilling R, Janssen HL, et al.Genetic characteristics ofhepatitis B virus genotypes as a factor for interferon-inducedHBeAg clearance[J].J Med Virol, 2007, 79 (8) :1055-1063.

[28]Senturk H, Baysal B, Tahan V, et al.Long-term effect of interferontherapy in patients with HBeAg positive chronic hepatitis B infection[J].Dig Dis Sci, 2011, 56 (1) :208-212.

[29]Perrillo R.Benefits and risks of interferon therapy for hepatitis B[J].Hepatology, 2009, 49 (5 Suppl) :103-111.

[30]沈建坤, 侯金林, 潘兴南, 等.HBV基因型与聚乙二醇干扰素疗效关系及病理变化[J].南方医科大学学报, 2008, 28 (7) :1217-1222.

[31]Bonino F, Marcellin P, Lau GKK, et al.Predicting response topeginterferonα-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B[J].Gut, 2007, 56 (5) :699-705.

[32]Flink HJ, van Zonneveld M, Hansen BE.et al.Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitise B:HBsAg loss is associated with HBV genotype[J].Am J Gastroen-terol, 2006, 101 (2) :297-303.

[33]Buster EH, Hansen BE, Lau GK, et al.Factors that predict re-sponse of patients with hepatitis B e antigen-positive chronic hepa-titis B to peginterferon-alfa[J].Gastro-Enterology, 2009, 137 (6) :2002-2009.

[34]Moucari R, Martinot-Peignoux M, Mackiewicz V, et al.Influenceof genotype on hepatitis B surface antigen kinetics in hepatitis B eantigen-negative patients treated with pegylated interferon-al-pha2a[J].Antivir Ther, 2009, 14 (8) :1183-1188.

[35]周冬生, 罗光汉, 江建宁, 等.B、C基因型与拉米夫定抗HBV疗效的比较[J].中国实用医药, 2008, 3 (13) :13-14.

[36]Enomoto M, Tamori A, Nishiguchi S.Hepatitis B virus genotypesand response to antiviral therapy[J].Clin Lab, 2006, 52 (1-2) :43-47.

[37]王芳, 郑岚.乙型肝炎病毒基因型与干扰素及拉米夫定抗病毒治疗相关性的探讨[J].中国医药导报, 2008, 5 (17) :30-31.

[38]Palumbo E.Hepatitis B genotypes and response to antiviral therapy:a review[J].Am J Ther, 2007, 14 (3) :306-309.

[39]Jardi R, Rodriguez-Frias F, Schaper M, et al.Analysis of hepati-tis B genotype changes in chronic hepatitis B infection:Influence ofantiviral therapy[J].J Hepatol, 2008, 49 (5) :695-701.

[40]Zalewska M, Domagaa M, Simon K, et al.Hepatitis B virus geno-types and the response to lamivudine therapy[J].Pol Arch MedWewn, 2005, 114 (6) :1190-1199.

[41]赵先胜.HBV不同基因与替比夫定抗病毒疗效关系探讨[J].海峡药学, 2010, 22 (5) :140-141.

[42]刘兴, 周陶友, 白浪, 等.HBV基因型和阿德福韦酯疗效之间关系的初步研究[J].华西医学, 2008, 23 (3) :533-535.

[43] 卢建溪, 王强, 陈文思, 等.阿德福韦酯抗病毒疗效与乙型肝炎病毒基因型的关系[J].中华生物医学工程杂志, 2009, 15 (3) :189-193.

[44]胡章勇, 杨军, 许颖, 等.阿德福韦酯治疗HBeAg阴性慢性乙型肝炎疗效与HBV基因型的关系[J].传染病信息, 2009, 22 (4) :219-221.

[45]Buti M, Elefsiniotis I, Jardi R, et al.Viral genotype and baseline loadpredict the response to adefovir treatment in lamivudine-resistant chro-nic hepatitis B patients[J].Hepatol, 2007, 47 (3) :366-372.

[46]Ai-Zhong, Hui Deng, Chung Yang, et al.Hepatitis B virus geno-type-associated variability in antiviral response to adefovir dipivoxiltherapy in Chinese Han Population[J].Tohoku J Exp Med, 2008, 216 (3) :205-211.

[47]李世波, 丁贤君, 李绍佐.乙型肝炎病毒基因型与阿德福韦酯治疗效应的关系[J].浙江中西医结合杂志, 2007, 17 (9) :532-534.

[48]徐严, 张永贵, 季尚玮, 等.乙型肝炎病毒基因型检测的临床意义[J].中国实验诊断学, 2010, 14 (1) :61-63.

[49] 徐严, 王江滨, 徐杰, 等.恩替卡韦治疗104例乙型肝炎肝硬化患者96周的疗效观察[J].中华肝脏病杂志, 2010, 18 (2) :109-112.

[50]Gish RG, Chang TT, Lai CL, et al.Loss of HBsAg antigen duringtreatment with entecavir or lamivudine in nucleoside-nave HBeAg-positive patients with chronic hepatitis B[J].J Viral Hepat, 2010, 17 (1) :16-22.

施引文献

资源附件(0)

访问统计